Accelerate Diagnostics
AXDX
AXDX was delisted on the 14th of May, 2025.
117 hedge funds and large institutions have $665M invested in Accelerate Diagnostics in 2017 Q4 according to their latest regulatory filings, with 23 funds opening new positions, 29 increasing their positions, 38 reducing their positions, and 24 closing their positions.
20% more funds holding in top 10
Funds holding in top 10: 5 → 6 (+1)
10% more capital invested
Capital invested by funds: $605M → $665M (+$60M)
1% less funds holding
Funds holding: 118 → 117 (-1)
4% less first-time investments, than exits
New positions opened: 23 | Existing positions closed: 24
11% less call options, than puts
Call options by funds: $15.2M | Put options by funds: $17.1M
24% less repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 38
Top Buyers
| 1 |
Balyasny Asset Management
Chicago,
Illinois
|
+$8.92M |
| 2 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$7.5M |
| 3 |
AG
Artal Group
Luxembourg
|
+$7.03M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$6.78M |
| 5 |
AAMU
Amundi Asset Management US
Boston,
Massachusetts
|
+$4.75M |
Top Sellers
| 1 |
PC
Polar Capital
London,
United Kingdom
|
-$23.3M |
| 2 |
MGM
Miura Global Management
New York
|
-$15.5M |
| 3 |
O
OppenheimerFunds
New York
|
-$5.95M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$4.43M |
| 5 |
Credit Agricole
Montrouge Cedex,
France
|
-$4.23M |
AXDX Hedge Fund Activity: Q4 2017 in Review
117 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Accelerate Diagnostics (AXDX) for Q4 2017, worth a combined $665M — up 9.9% from $605M a quarter earlier.
Sellers outnumbered buyers: 24 funds closed out of AXDX and 23 opened new positions — a net loss of 1 holder — while 38 trimmed existing stakes and 29 added.
The largest buyer was Balyasny Asset Management, opening a new position worth an estimated $8.92M. The largest seller was Polar Capital, exiting entirely with an estimated $23.3M sold.
- 117 institutional investors held Accelerate Diagnostics (AXDX) as of Q4 2017, down from 118 in Q3 2017.
- Funds reported $665M of Accelerate Diagnostics stock for Q4 2017, up 9.9% quarter-over-quarter.
- 23 funds opened new Accelerate Diagnostics positions in Q4 2017 and 24 closed out, a net change of -1 holder.
- The largest Accelerate Diagnostics buyer in Q4 2017 was Balyasny Asset Management, an estimated $8.92M added.
- The largest Accelerate Diagnostics seller in Q4 2017 was Polar Capital, an estimated $23.3M sold.
Based on aggregated 13F filings for Q4 2017.